二、关于 2023 年半年度募集资金存放与使用情况专项报告的独立意见 天津九安医疗电子股份有限公司独立董事 关于公司第六届董事会第五次会议相关事项的独立意见 根据《上市公司独立董事规则》《上市公司自律监管指引第 1 号——主板上 市公司规范运作》及《独立董事制度》等有关规定，作为天津九安医疗电子股份 有限公司（以下简称"公司"）的独立董事，本着对公司、全体股东及投资者负责 的态度，经认真审议公司第六届董事会第五次会议的相关议案后，发表如下独立 意见： 一、关于控股股东及其他关联方占用公司资金、公司对外担保等情况的专项 说明和独立意见 1、关于报告期内的关联方占用资金情况 报告期内，公司不存在控股股东及除合并报表范围内子公司外的其他关联方 占用公司资金或变相占用公司资金的情况。 2、关于报告期内的对外担保情况 报告期内，公司无新增对外担保事项。公司不存在对合并报表范围以外的法 人或自然人进行担保的情况，不存在违反规定对外担保事项。 公司已建立了较为健全的《对外担保制度》《防范大股东及其关联方资金占 用制度》等内控制度，能够认真贯彻执行有关规定，不存在损害公司及公司股东 尤其中小股东权益的情形。 经核查，我们认为 ...

关于调整自有资金证券投资额度的公告 证券代码：002432 证券简称：九安医疗 公告编号：2023-045 天津九安医疗电子股份有限公司 本公司及董事会全体成员保证公告内容真实、准确和完整， 并对公告中的虚假记载、误导性陈述或者重大遗漏承担连带责任。 天津九安医疗电子股份有限公司（以下简称"公司"）第六届董事会第二次 会议以及 2023 年第一次临时股东大会审议通过了《关于使用自有资金进行委托 理财与证券投资的公告》，同意公司使用最高额度合计不超过（含）30 亿元人民 币或等值外币的自有资金进行证券投资，期限为 12 个月，可由公司及子公司共 同循环滚动使用。详见公司于 2023 年 2 月 1 日披露在巨潮资讯网上的《关于使 用自有资金进行委托理财与证券投资的公告》（公告编号：2023-006）。 为进一步提高自有资金的使用效率和效益，公司于 2023 年 8 月 29 日召开了 第六届董事会第五次会议，审议通过了《关于调整自有资金证券投资额度的议案》， 同意在保障公司正常经营运作资金需求的情况下，将使用自有资金进行证券投资 的额度由不超过 30 亿元人民币或等值外币调整为不超过 60 亿元人民币或等值 外 ...

证券代码：002432 证券简称：九安医疗 公告编号：2023-043 天津九安医疗电子股份有限公司 2023年半年度募集资金存放与使用情况专项报告 本公司及董事会全体成员保证公告内容真实、准确和完整， 并对公告中的虚假记载、误导性陈述或者重大遗漏承担连带责任。 一、募集资金基本情况 天津九安医疗电子股份有限公司（以下简称"公司"）经中国证券监督管理委员 会（以下简称"中国证监会"）《关于核准天津九安医疗电子股份有限公司非公开发行 股票的批复》（证监许可[2020]3324 号）核准，公司 2020 年度非公开发行人民币普 通股(A 股)股票 45,797,101 股，每股面值为人民币 1.00 元，发行价为每股人民币 6.90 元，募集资金总额为人民币 315,999,996.90 元，扣除与发行有关的费用 6,630,702.76 元后，实际募集资金净额为人民币 309,369,294.14 元。上述募集资金 到位情况已经大华会计师事务所（特殊普通合伙）验证并出具《天津九安医疗电子 股份有限公司非公开发行人民币普通股（A 股）的验资报告》（大华验字[2021]000141 号）。 | 项目 | 金额（人民 ...

2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：天津九安医疗电子股份有限公司 单位：万元 | 其他关联 | | 往来方与上市 | 上市公司核算 | 2023 2023 年期初 | 年度往来 | 2023 年度往来 | 2023 | 年度偿还累 2023 | 年期末往 | 往来形成原 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 资金往来 | 资金往来方名称 | 公司的关联关 | 的会计科目 | 往来资金余额 | 累计发生额（不 | 资金的利息 | 计发生金额 | | 来资金余额 | 因 | 往来性质 | | | | 系 | | | 含利息） | | | | | | | | | 柯顿（天津）电子医疗器械有限 | 全资子公司 | 其他应收款 | 17,977.79 | 7,335.29 | | | 6,837.19 | 18,475.89 | 代垫费用 | 经营性往来 | | | 公司 | | | | | | | | | | | | | 泰安九德电子科技有限公司 | 全资子公 ...

证券代码：002432 证券简称：九安医疗 公告编号：2023-044 天津九安医疗电子股份有限公司 关于回购公司股份方案的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对 公告中的虚假记载、误导性陈述或者重大遗漏承担连带责任。 重要内容提示： 1、由于天津九安医疗电子股份有限公司(以下简称"公司")二级市场股票价 格低于公司最近一期每股净资产，公司管理层认为股价已经偏离了公司基本面。 为维护公司价值及股东权益，公司拟使用自有资金通过二级市场以集中竞价交易 的方式回购公司部分社会公众股份（以下简称"本次回购"）。本次回购的资金 总额不低于 50,000 万元人民币(含)且不超过 100,000 万元人民币(含)。本次回 购股份的价格为不超过人民币 49.00 元/股（含），若按回购资金总额上限和回购 股份价格上限进行测算，预计可回购股份数量约为 20,408,100 股，约占公司当前 总股本的 4.20%；按回购资金总额下限和回购股份价格上限测算，预计可回购股 份数量约为 10,204,000 股，约占公司当前总股本的 2.10%。若公司在回购期间实 施了送股、资本公积转增股本、现金分红、配股等 ...

证券代码：002432 证券简称：九安医疗 公告编号：2023-039 天津九安医疗电子股份有限公司 关于举行2023年半年度网上业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整， 并对公告中的虚假记载、误导性陈述或者重大遗漏承担连带责任。 天津九安医疗电子股份有限公司（以下简称"公司"）2023 年半年度报告 定于 2023 年 8 月 30 日披露于《中国证券报》《证券时报》和巨潮资讯网 （www.cninfo.com.cn），为了让广大投资者能进一步了解公司 2023 年半年度的 经营情况，公司将于 2023 年 8 月 30 日下午 15:00-16:30 在东方财富平台举行 2023 年 半 年 度 网 上 业 绩 说 明 会 。 投 资 者 可 登 陆 东 方 财 富 路 演 平 台 （http://roadshow.eastmoney.com/luyan/4334466）进行参与，本次业绩说明 会将采用线上文字交流的方式。 本次说明会出席人员：公司董事长兼总经理刘毅先生，董事、副总经理王湧 先生，董事、副总经理丛明先生，独立董事孙卫军先生，董事会秘书邬彤先生， 财务经理秦菲女 ...

证券代码：002432 证券简称：九安医疗 问题 2:2022 年的公司分红方案不理解，投资者回报公司时怎么考虑的， 尤其是中小投资者 回复:您好，公司一贯重视投资者回报，注重维护公司和全体股东的权益， 近年来自满足分红条件的年度开始，持续进行现金分红。公司近年来的 利润分配预案均符合分红相关法律法规以及《公司章程》的规定，是在 兼顾公司未来发展规划以及股东利益的基础上制定的。2020 年度现金分 红达 2800 万元，2021 年度现金分红达 3.19 亿元，回购约 2 亿元(根据 规定视为当年现金分红)，2022 年度拟现金分红 11.77 亿元。近三年累 计现金分红金额达母公司可分配利润的 90%以上，且超过近三年平均合 并报表净利润的 30%。按照今天收盘价测算，公司股息率约为 6%。公司 在经营发展和股东回报方面有持续规划，会按照相关规定制定利润分配 方案，期待大家共同关注公司长远发展，公司希望以良好的业绩回报一 直以来支持公司的投资者，感谢您的关注。 问题 3:董秘您好！2022 年 11 月 22 日与美国签定的大合同，未履行的 原因是什么？是九安的交货出了问题？还是美国买方的问题？九安在 签合 ...

Financial Performance - The company's operating revenue for 2022 reached ¥26,315,360,917.43, representing a 997.80% increase compared to ¥2,397,097,777.49 in 2021[22] - Net profit attributable to shareholders for 2022 was ¥16,030,169,077.77, a significant increase of 1,664.19% from ¥908,642,433.60 in the previous year[22] - The net profit after deducting non-recurring gains and losses was ¥16,357,536,402.34, up 1,888.82% from ¥822,474,021.86 in 2021[22] - Cash flow from operating activities netted ¥18,221,682,959.48, a remarkable increase of 6,116.59% compared to ¥293,114,031.60 in 2021[22] - Basic earnings per share for 2022 were ¥35.1382, reflecting a 1,657.79% increase from ¥1.9990 in 2021[22] - Total assets at the end of 2022 amounted to ¥21,730,643,774.98, a 452.90% increase from ¥3,930,327,210.41 at the end of 2021[22] - The net assets attributable to shareholders reached ¥19,554,218,225.76, up 580.72% from ¥2,872,576,259.56 in the previous year[22] Dividend Distribution - The company plans to distribute a cash dividend of ¥25 per 10 shares (including tax) to all shareholders[4] - The company reported a cash dividend of RMB 1,177,454,977.50, with a distribution of RMB 25.00 per 10 shares[151] - The total distributable profit was RMB 1,263,068,494.03, with the cash dividend accounting for 100% of the profit distribution[151] Market Strategy and Product Development - The core strategy focuses on promoting the "O+O" model for diabetes care in China and the United States, along with the development of blockbuster products[16] - The company emphasizes the integration of smart hardware, apps, and cloud platforms in its diabetes care services[16] - The company is focusing on diabetes management as a core strategy, promoting the "O+O" model for comprehensive care in both China and the U.S.[37] - The company is developing a Continuous Glucose Monitoring System (CGMS) to enhance diabetes management[43] - The company plans to invest CNY 2.09 billion in the "Diabetes Care Service and Related Product R&D Project," with CNY 0.40 billion allocated for operations in Tianjin and CNY 1.69 billion for services in Beijing and other regions[102] Sales and Revenue Growth - In Q1 2022, the company reported a total revenue of approximately ¥21.74 billion, with a net profit attributable to shareholders of about ¥14.31 billion[26] - The iHealth test kit sales revenue increased by 1,296.27% year-on-year, with a gross margin of 80.32%[39] - The company expanded its production capacity from 1 million to 20 million test kits per day within three months[38] - The company achieved a significant increase in production capacity for iHealth test kits, scaling from an initial daily output of 1 million units to 10 million units, and subsequently to 20 million units within three months[54] - Domestic sales increased by 96.28% to ¥441,835,099.43, while international sales surged by 1,091.23% to ¥25,873,525,818[66] Research and Development - Research and development expenses increased by 296.95% to ¥264,888,760.12, primarily due to increased R&D activities and employee stock payment expenses[76] - The company increased its R&D investment to approximately ¥283.42 million in 2022, a significant increase of 151.89% compared to ¥112.52 million in 2021[79] - The number of R&D personnel rose to 407 in 2022, reflecting an increase of 11.51% from 365 in 2021[79] Corporate Governance - The company has maintained compliance with corporate governance regulations, ensuring no significant discrepancies with legal requirements[123] - The company has established four specialized committees under the board: Strategy Committee, Nomination Committee, Compensation and Assessment Committee, and Audit Committee, which provide scientific and professional advice for decision-making[123] - The company operates independently from its controlling shareholders in all aspects, including business, personnel, assets, and finance, ensuring complete operational autonomy[124] Internal Control and Risk Management - The company has implemented a robust internal control and management system to support its operational stability and performance[122] - The company has not reported any significant defects in its internal control during the reporting period[169] - The company maintained effective internal control over financial reporting as of December 31, 2022, with no significant deficiencies identified[172] Employee Management and Incentives - The company has implemented stock option and employee stock ownership plans to enhance long-term incentive mechanisms and attract talent[114] - The employee stock ownership plan includes participation from 702 employees, including senior management and key technical personnel[165] - The company’s senior management is evaluated annually based on their work performance and the achievement of company goals, which effectively incentivizes management[164] Market Position and Competition - The company faces risks related to market competition and the need to differentiate its products in performance, price, and user experience[112] - The company is focused on expanding its market presence and enhancing its product offerings through new technology development and strategic initiatives[119] Environmental and Social Responsibility - The company has implemented a paperless office system to promote environmental sustainability and reduce carbon emissions[174] - The company has not faced any administrative penalties related to environmental issues during the reporting period[174] - The company has committed to continuous product innovation and quality improvement to meet customer needs[177]

Financial Performance - The company's revenue for Q1 2023 was ¥1,495,439,073.13, a decrease of 93.12% compared to ¥21,736,870,739.50 in the same period last year[3] - Net profit attributable to shareholders was ¥601,496,251.76, down 95.80% from ¥14,311,867,476.47 year-on-year[3] - The basic earnings per share decreased to ¥1.2772, a decline of 95.93% from ¥31.3920 in the previous year[3] - Total operating revenue for Q1 2023 was CNY 1,495,439,073.13, a significant decrease from CNY 21,736,870,739.50 in the same period last year[13] - Net profit for Q1 2023 was CNY 715,140,634.14, compared to CNY 15,257,942,841.81 in Q1 2022, indicating a substantial decline[14] - The total comprehensive income for the first quarter was CNY 454,029,305.09, compared to CNY 15,245,031,404.27 in the previous period[15] Assets and Liabilities - The total assets at the end of the reporting period were ¥22,127,092,267.00, an increase of 1.82% from ¥21,730,643,774.98 at the end of the previous year[3] - The company's total assets increased to CNY 22,127,092,267.00 from CNY 21,730,643,774.98 year-over-year[12] - Total liabilities decreased to CNY 1,547,470,889.80 from CNY 1,705,942,406.46 in the previous year[12] - The company's equity attributable to shareholders rose to CNY 20,003,813,439.49, up from CNY 19,554,218,225.76 year-over-year[12] Cash Flow - Cash flow from operating activities was ¥774,274,874.97, down 93.91% from ¥12,719,185,146.12 in the same period last year[3] - Net cash flow from operating activities was CNY 774,274,874.97, significantly lower than CNY 12,719,185,146.12 in the previous period[16] - The company reported a decrease in cash flow from operating activities, with cash inflows totaling CNY 1,589,084,110.25, down from CNY 17,833,437,850.37 in the previous period[16] - Cash inflow from investment activities totaled CNY 3,305,853,178.30, compared to CNY 219,398,566.33 in the previous period[17] - Net cash flow from investment activities was negative at CNY -732,707,257.50, compared to CNY -114,035,009.53 in the previous period[17] - The cash and cash equivalents at the end of the period stood at CNY 5,527,897,584.36, down from CNY 12,938,770,737.53 in the previous period[17] Expenses - Operating costs for Q1 2023 amounted to CNY 785,986,402.06, down from CNY 4,844,206,985.44 year-over-year[13] - The company reported a significant reduction in sales and management expenses, with sales expenses down 74.86% and management expenses down 46.32% compared to the previous year[6] - Research and development expenses for Q1 2023 were CNY 72,848,101.89, an increase from CNY 60,553,065.68 in the same quarter last year[13] Shareholder Information - The total number of common shareholders at the end of the reporting period is 149,933[8] - The largest shareholder, Shihezi Sanhe Equity Investment Partnership, holds 24.05% of the shares, totaling 116,544,519 shares[8] - The company does not have any preferred shareholders as per the report[9] - The company is unaware of any relationships or concerted actions among the top 10 shareholders[9] Investment Activities - Investment cash payments increased to ¥4,028,962,710.43, a rise of 1651.72% compared to ¥230,000,000.00 in the previous year[7] - The company experienced a 1401.24% increase in cash received from investment, totaling ¥3,190,121,655.58, compared to ¥212,498,566.33 last year[7] - The company reported an investment income of CNY 119,787,222.87, a recovery from a loss of CNY 1,919,799.05 in the previous year[14] Other Financial Metrics - The weighted average return on equity dropped to 3.02%, a decrease of 139.69% from 142.71% in the previous year[3] - Deferred tax assets increased to CNY 79,507,917.00 from CNY 52,521,826.08 year-over-year[12] - The company's cash and cash equivalents at the end of Q1 2023 amount to ¥5,562,835,995.14, an increase from ¥5,443,937,803.45 at the beginning of the year[10] - The total current assets are reported at ¥12,924,564,815.71, down from ¥13,194,977,225.32 at the beginning of the year[10] - The company's trading financial assets are valued at ¥6,115,301,829.58, compared to ¥6,044,046,377.99 at the start of the year[10] - Accounts receivable decreased to ¥382,526,668.11 from ¥391,761,721.40[10] - Inventory has decreased to ¥501,666,083.77 from ¥697,614,358.66[10] Audit Status - The report was not audited, indicating that the figures presented are preliminary and subject to change[18]

证券代码：002432 证券简称：九安医疗 公告编号：2023-023 天津九安医疗电子股份有限公司关于举行 2022年度及2023年第一季度网上业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整， 并对公告中的虚假记载、误导性陈述或者重大遗漏承担连带责任。 天津九安医疗电子股份有限公司（以下简称"公司"）2022 年年度报告、 2023 年 第 一 季 度 报 告 定 于 2023 年 4 月 29 日 披 露 于 巨 潮 资 讯 网 （www.cninfo.com.cn），为了让广大投资者能进一步了解公司 2022 年年度、2023 年第一季度的经营情况，公司将于 2023 年 5 月 5 日下午 15:00-16:30 在同花顺 举行 2022 年度及 2023 年第一季度网上业绩说明会。本次业绩说明会将采用网络 远程文字交流的方式举行，本次年度报告说明会将采用网络远程方式举行，投资 者可登陆同顺路演平台（https://board.10jqka.com.cn/ir）或者同花顺 App 端入口（同花顺 App 首页-搜索-路演平台）参与本次说明会。 出席本次说明会的人员有：公司董事长兼 ...